Latest From VLST Corp.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
The private US biotechnology firm VLST has added oncology to its list of targeted disease areas, on top of autoimmune and inflammatory disorders, by in-licensing the anti-CD40 monoclonal antibody CP-870,893 from Pfizer, which has taken a 5% equity position in VLST and is entitled to milestone payments from the development programme.
The US biotechnology company Oncothyreon has appointed Julie Eastland chief financial officer and vice-president of corporate development. Ms Eastland previously served as CFO and vice-president of finance and operations at VLST, a privatelyheld biotech company, as well as finance positions at Dendreon, Amgen and Encore Media Group.
Corporate venture funds are taking an increasingly high-profile role in biotech financing deals. Eva Jack and Dr Maggie Flanagan LeFlore, managing directors of MedImmune Ventures, explain to Pete Chan why their drivers are both financial and strategic.
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- VLST Corp.
- Senior Management
Martin A Simonetti, Pres. & CEO
Teresa M Foy, PhD, CSO
Brian Blackman, VP, Fin. & Admin.
Rob Myers, VP, Corp. Dev.
- Contact Info
Phone: (206) 262-5500
307 Westlake Ave. N.
Seattle, WA 98109
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.